<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060242</url>
  </required_header>
  <id_info>
    <org_study_id>ICC2302</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-ICC-2302</secondary_id>
    <nct_id>NCT00060242</nct_id>
  </id_info>
  <brief_title>Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer</brief_title>
  <official_title>Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by&#xD;
      stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in&#xD;
      treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate of patients with advanced anaplastic thyroid&#xD;
           cancer treated with combretastatin A4 phosphate.&#xD;
&#xD;
        -  Determine whether this drug alters the natural history of anaplastic thyroid cancer, in&#xD;
           terms of doubling the median survival from 4-6 months to 12 months, in these patients.&#xD;
&#xD;
        -  Determine the safety profile of this drug in these patients.&#xD;
&#xD;
        -  Correlate clinical response with pretreatment tumor microvessel density and immature&#xD;
           vessel staining, changes in sICAM-1 levels over the course of treatment, and&#xD;
           pharmacokinetic parameters in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving a complete response (CR) receive 2 courses beyond documentation of the CR.&#xD;
&#xD;
      Patients are followed monthly.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study within 18-24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median survival</measure>
    <time_frame>every 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective disease response</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosbretabulin disodium</intervention_name>
    <description>Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.</description>
    <other_name>Combretastatin A4 phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed* anaplastic or poorly differentiated variant thyroid cancer,&#xD;
             including 1 of the following:&#xD;
&#xD;
               -  Recurrent/regionally advanced disease no longer amenable to definitive curative&#xD;
                  surgery or radiotherapy&#xD;
&#xD;
               -  Untreated metastatic disease NOTE: *If original/diagnostic tumor blocks are&#xD;
                  unavailable, tumor must be accessible for pretreatment core needle biopsy&#xD;
&#xD;
          -  Must have relapsed or progressed during or after prior combined modality therapy&#xD;
             (e.g., systemic chemotherapy and radiotherapy) for regionally advanced (but not&#xD;
             metastatic) disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Patent trachea and airway by screening direct and indirect laryngoscopy* NOTE: *For&#xD;
             patients with bulky thyroid/neck masses and/or suspected airway obstruction&#xD;
&#xD;
          -  No active brain metastases, as evidenced by any of the following:&#xD;
&#xD;
               -  Symptomatic involvement&#xD;
&#xD;
               -  Cerebral edema by CT scan or MRI&#xD;
&#xD;
               -  Radiographic evidence of progression since definitive therapy&#xD;
&#xD;
               -  Continued requirement for corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.5 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST no greater than 3.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 50% by MUGA&#xD;
&#xD;
          -  EKG normal&#xD;
&#xD;
               -  No evidence of prior myocardial infarction (e.g., significant Q waves), QTc&#xD;
                  greater than 450 msec, or other clinically significant abnormalities&#xD;
&#xD;
          -  No history of angina (even if controlled by medication)&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No uncontrolled atrial arrhythmias&#xD;
&#xD;
          -  No clinically significant arrhythmias, including any of the following:&#xD;
&#xD;
               -  Conduction abnormalities&#xD;
&#xD;
               -  Nodal junctional arrhythmias and dysrhythmias&#xD;
&#xD;
               -  Sinus bradycardia or tachycardia&#xD;
&#xD;
               -  Supraventricular arrhythmias&#xD;
&#xD;
               -  Atrial fibrillation or flutter&#xD;
&#xD;
               -  Syncope or vasovagal episodes&#xD;
&#xD;
          -  No significant heart wall abnormality or heart muscle damage by MUGA&#xD;
&#xD;
          -  No uncontrolled hypertension (blood pressure consistently greater than 150 mm Hg&#xD;
             systolic and 100 mm Hg diastolic regardless of medication)&#xD;
&#xD;
               -  Patients with previous hypertension are allowed provided there is clinical&#xD;
                  documentation of controlled blood pressure for 2 months prior to study enrollment&#xD;
&#xD;
          -  No symptomatic peripheral vascular disease&#xD;
&#xD;
          -  No symptomatic cerebrovascular disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No grade 2 or greater preexisting motor or sensory peripheral neuropathy&#xD;
&#xD;
          -  No uncontrolled hypokalemia or hypomagnesemia&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No other nonmalignant medical illness that is uncontrolled or whose control may be&#xD;
             jeopardized by study therapy&#xD;
&#xD;
          -  No psychiatric disorders or other conditions that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic colony-stimulating factors (e.g., filgrastim [G-CSF] or&#xD;
             sargramostim [GM-CSF])&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy, except any of the following:&#xD;
&#xD;
               -  Gonadotropin-releasing hormone agonists for hormone-refractory prostate cancer&#xD;
&#xD;
               -  Hormone replacement therapy&#xD;
&#xD;
               -  Oral contraceptives&#xD;
&#xD;
               -  Megestrol for anorexia/cachexia&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy with progressive disease beyond radiation&#xD;
             ports&#xD;
&#xD;
          -  No prior radiotherapy to more than 30% of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 6 weeks since other prior therapy associated with delayed toxicity&#xD;
&#xD;
          -  No prior therapy for metastatic disease&#xD;
&#xD;
          -  No concurrent medication(s) known to prolong the QTc interval, unless medication(s)&#xD;
             can be held for at least 72 hours before, during, and for at least 6 hours after study&#xD;
             drug administration&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent antineoplastic or cytotoxic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panayiotis Savvides, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009 Mar;19(3):233-40. doi: 10.1089/thy.2008.0321.</citation>
    <PMID>19265494</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Panayiotis Savvides, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fosbretabulin</mesh_term>
    <mesh_term>Combretastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

